Recent Articles

• 
  Medical / Research

  Origin cells of refractory brain tumors identified

  A research team from KAIST and Yonsei University Severance Hospital has for the first time shown that intractable brain tumors common in younger people originate from “founder cells” in the brain that appear normal. Image created with generative AI. Provided by KAIST A domestic research team has, fo

  2026.01.09
• 
  Clinical Trial

  Hanmi Starts Phase 2 Melanoma Drug Trial in Korea

  Hanmi Pharmaceutical headquarters Hanmi Pharmaceutical has become the first in Korea to initiate a Phase 2 clinical trial of a targeted anti-cancer drug for the treatment of melanoma, a malignant skin cancer. Expectations are high for an innovative new drug that can alleviate patient suffering in a

  2026.01.08
• 
  Investment / Pharmaceutical R&D

  Celltrion Outlines Growth Strategy at JPM Healthcare Conference

  Celltrion announced on the 7th that Seo Jin-seok, CEO of the Business Management Division, and Executive Vice President Lee Hyuk-jae will attend the “2026 JP Morgan Healthcare Conference (JPM),” the world’s largest pharmaceutical and biotech investment event, to present the company’s new drug develo

  2026.01.07
• 
  MedTech

  Noninvasive Test Detects Heart and Tendon Health

  Professor Kim Cheolhong (left), Professor Jang Jina. POSTECH announced on the 6th that a research team at its Graduate School of Convergence Science and Technology has recently developed a new microscopy technology that can precisely analyze the health status of tissues such as the heart and tendons

  2026.01.07
• 
  MedTech

  Varicose Vein Device Nuvana Wins MFDS Approval

  As the number of modern people spending long hours sitting increases, the number of patients with varicose veins in the lower extremities has also been steadily rising. Against this backdrop, a domestic bio company has developed a medical device for treating varicose veins and has begun full-scale s

  2026.01.06
• 
  Global Expansion / Celltrion

  Celltrion’s U.S. Plant Deal Eases Risks, Lifts Earnings

  The Eli Lilly pharmaceutical production plant in Branchburg, New Jersey, acquired by Celltrion. Celltrion announced on the 2nd that it has completed the transfer and related procedures (deal closing) for the biopharmaceutical production facility in Branchburg, New Jersey, United States, acquired fro

  2026.01.02
• 
  AI·Healthcare

  KAIST Develops AI-Based Personalized Cancer Vaccine Design

  Professor Choi Jeong-gyun of the Department of Bio and Brain Engineering at KAIST (left) and his research team. Provided by KAIST The KAIST research team has developed an artificial intelligence (AI)-based anticancer vaccine design technology capable of creating “personalized cancer vaccines.” Unlik

  2026.01.02
• 
  MedTech

  From Taiwan Chips to Global Medical AI: Wonju Summit

  Colley Hwang, chairman of DIGITIMES, delivers a lecture at the “Wonju, a Digital Health AI-Centric City” event held at Yonsei University Mirae Campus. The Wonju City Government and Leadtek Korea held a lecture titled “Wonju, a Digital Health AI-Centric City” at Yonsei University Mirae Campus on the

  2025.12.30
• 
  Medical / Research

  Waking Dormant Immune Cells to Attack Tumors

  Schematic diagram of an in vivo CAR-macrophage generation and cancer cell-killing strategy via simultaneous delivery of CAR mRNA and an immune stimulant using lipid nanoparticles (provided by KAIST) / News1 A Korean research team has developed a therapy that awakens dormant immune cells inside solid

  2025.12.30
• 
  MedTech

  Bigcare Earns ISO 27799 Medical Data Security Certification

  Healthcare platform company BIGCARE announced that on the 19th it obtained three certifications for international information security standards established by the International Organization for Standardization (ISO): △ISO 27001 (Information Security Management System), △ISO 27701 (Privacy Informati

  2025.12.30